Competing designs for drug combination in phase I dose-finding clinical trials.

@article{Riviere2015CompetingDF,
  title={Competing designs for drug combination in phase I dose-finding clinical trials.},
  author={M-K Riviere and Fanny Dubois and Sarah Zohar},
  journal={Statistics in medicine},
  year={2015},
  volume={34 1},
  pages={1-12}
}
The aim of phase I combination dose-finding studies in oncology is to estimate one or several maximum tolerated doses (MTDs) from a set of available dose levels of two or more agents. Combining several agents can indeed increase the overall anti-tumor action but at the same time also increase the toxicity. It is, however, unreasonable to assume the same dose-toxicity relationship for the combination as for the simple addition of each single agent because of a potential antagonist or synergistic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
8 Citations
24 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Team

  • R Development Cor
  • R: A Language and Environment for Statistical…
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…